Market News & Trends
Global Gene Therapy Deals Sky-Rocketed to Nearly $5 Billion in 2014
The total number of deals in the global gene therapy market more than doubled from 16 in 2013 to 36 in 2014, with their combined…
Bristol-Myers Squibb Will Win Big with Melanoma Combination Immunotherapy
Data presented at the recent American Society of Clinical Oncology (ASCO) Annual Meeting 2015 by Bristol-Myers Squibb (BMS) suggests that its Opdivo/Yervoy combination of immunotherapies…
SIGNiX & Exostar Partner to Deliver Secure, Compliant Digital Signature Solution to Life Science & Healthcare
Researchers, Clinical Trial Participants, Physicians and Others Can Access Cloud-Based Independent E-Signatures™ via the Exostar Life Sciences Identity Hub CHATTANOOGA, Tenn., June 18, 2015 –…
PlasmaTech Announces Name Change to Abeona Therapeutics; Reflects Broader Rare Disease Commitment
PlasmaTech Biopharmaceuticals, Inc. (NASDAQ: PTBI), a biopharmaceutical company focused on developing and delivering gene therapy and plasma-based products for severe and life-threatening rare diseases, recently…
Taiho & Servier Enter Into Exclusive License Agreement
Taiho Pharmaceutical Co., and Servier recently announced they have entered into an exclusive license agreement for the development and commercialization of TAS-102 (non-proprietary names: trifluridine…
PDC*line Pharma Receives Advanced-Therapy Medicinal Product Classification for New Class of Therapeutic Cancer Vaccines
PDC*line Pharma recently announced that PDC*vac, its new class of therapeutic cancer vaccines based on a line of Plasmacytoid Dendritic Cells (PDC*line), was granted Advanced-Therapy…
ONL Therapeutics Provides Update on Novel Photoreceptor Protection Platform
ONL Therapeutics, Inc. recently provided an update on the company’s ongoing drug development program to block the programmed cell death (apoptosis) of photoreceptors. Death of…
LDC to Collaborate With Johnson & Johnson to Identify & Accelerate Innovative Drug Candidates
The Lead Discovery Center GmbH (LDC) and Johnson & Johnson Innovation Ltd., will collaborate to identify and accelerate innovative drug candidates for the treatment and…
Recipharm Completes Acquisition; Broadens Development Capabilities
Recipharm recently announced that it has completed the acquisition of OnTarget Chemistry in Uppsala, Sweden. OnTarget Chemistry is a fast growing CRO company with a…
Emulate Announces Strategic Collaboration With Johnson & Johnson Innovation to Use Organs-on-Chips Platform
Emulate, Inc. recently announced that it recently formed a research collaboration with Janssen Biotech, Inc., a Janssen Pharmaceutical Company of Johnson & Johnson (Janssen), to…
Pancreatic Cancer Treatment Pipeline Dominated by Early Stage Development
While the treatment pipeline for pancreatic cancer shows a high level of innovation, with 52% of products categorized as first-in-class, most development is in the…
Ajinomoto Althea Receives European GMP Certification for Commercial Aseptic Filling & Testing
Ajinomoto Althea, Inc. (Althea), a leading provider of biopharmaceutical contract development and manufacturing services announced today that it has officially received its European GMP certificate…
FDA Awards Isarna Orphan Drug Designation
Isarna Therapeutics recently announced that the Food and Drug Administration (FDA) has granted orphan drug designation for ISTH0036, a locked nucleic acid-modified antisense oligonucleotide, for…
Mylan Launches First Bioequivalent Alternative to Combination Asthma Therapy
Mylan N.V. recently announced it has launched the first bioequivalent alternative to GlaxoSmithKline’s Seretide Evohaler (salmeterol xinafoate/fluticasone propionate) under the brand name Sirdupla in the…
Melinta Therapeutics Announces Financing to Fund Completion of Final Phase III Study
Melinta Therapeutics recently announced the successful completion of a $67-million Series 4 equity financing. Malin Corporation plc led the round and was joined by other…
Vericel Announces Plan to Submit Biologics License Application to the FDA
Vericel Corporation recently announced that following discussions with the US Food and Drug Administration (FDA), the company plans to submit a Biologics License Application (BLA)…
Concert Pharmaceuticals Receives $50-Million Payment From Auspex Pharmaceuticals
Concert Pharmaceuticals, Inc. recently announced that it has received a payment of $50.2 million from Auspex Pharmaceuticals, Inc. The payment is pursuant to a September…
Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio
Immune Pharmaceuticals Inc. recently announced it has entered into a binding Memorandum of Understanding with Yissum, the Technology Transfer Company of the Hebrew University of…
BIND Therapeutics & Macrophage Therapeutics Announce Collaboration to Engineer CD206 Targeted Accurin Nanoparticle Using Manocept Macrophage Targeting Platform
BIND Therapeutics, Inc. and Macrophage Therapeutics recently announced they have entered into a research collaboration to engineer Accurins with the Manocept™ targeting platform that enables…
Targeted Therapeutics & Nanoparticles
A key objective of pharmaceutical and biopharmaceutical development is to increase product therapeutic specificity and safety. Some of the recent exciting developments have obviously been…